Contrasting of Celgene Corporation (CELG) and Alpine Immune Sciences Inc. (NASDAQ:ALPN)

We are comparing Celgene Corporation (NASDAQ:CELG) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) on their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celgene Corporation 15.28B 4.11 4.05B 5.57 12.34
Alpine Immune Sciences Inc. N/A 126.12 29.67M -1.98 0.00

Demonstrates Celgene Corporation and Alpine Immune Sciences Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 shows us Celgene Corporation and Alpine Immune Sciences Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celgene Corporation 26.51% 56.8% 8.7%
Alpine Immune Sciences Inc. 0.00% -43.3% -39.1%

Volatility and Risk

A 1.47 beta means Celgene Corporation’s volatility is 47.00% more than S&P 500’s volatility. In other hand, Alpine Immune Sciences Inc. has beta of 0.89 which is 11.00% less volatile than S&P 500.


2.1 and 2 are the respective Current Ratio and a Quick Ratio of Celgene Corporation. Its rival Alpine Immune Sciences Inc.’s Current and Quick Ratios are 9.2 and 9.2 respectively. Alpine Immune Sciences Inc. has a better chance of clearing its pay short and long-term debts than Celgene Corporation.

Analyst Ratings

In next table is given Celgene Corporation and Alpine Immune Sciences Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Celgene Corporation 0 6 2 2.25
Alpine Immune Sciences Inc. 0 0 0 0.00

Celgene Corporation’s downside potential currently stands at -1.75% and an $88.17 consensus price target.

Institutional & Insider Ownership

The shares of both Celgene Corporation and Alpine Immune Sciences Inc. are owned by institutional investors at 76.3% and 54.8% respectively. Insiders owned 0.33% of Celgene Corporation shares. Insiders Comparatively, owned 28.26% of Alpine Immune Sciences Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Celgene Corporation -4.9% -8.98% -22.96% -12.32% -33.15% -34.19%
Alpine Immune Sciences Inc. 0% -0.47% -27.16% -47.88% -53.22% -57.14%

For the past year Celgene Corporation was less bearish than Alpine Immune Sciences Inc.


Celgene Corporation beats on 9 of the 11 factors Alpine Immune Sciences Inc.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.